deltatrials
Terminated PHASE2 INTERVENTIONAL 1-arm NCT04837131

A Study to Evaluate the Safety and Tolerability of Oral Ixazomib in Scleroderma-related Lung Disease Patients

A Phase 2 Open-Label Pilot Study of the Safety and Tolerability of Ixazomib Administered Orally to Patients With Scleroderma-Related Interstitial Lung Disease

Sponsor: Michael M. Pham

Conditions Diffuse Cutaneous Scleroderma Diffuse Cutaneous Systemic Sclerosis Diffuse Scleroderma Diffuse Systemic Sclerosis Interstitial Lung Disease Progressive Scleroderma Progressive Systemic Sclerosis Pulmonary Fibrosis Interstitial Scleroderma Scleroderma With Pulmonary Involvement Scleroderma of Lung Scleroderma, Diffuse Scleroderma, Systemic Scleroderma;Progressive Systemic Sclerosis Systemic Sclerosis Pulmonary Systemic Sclerosis With Lung Involvement Systemic Sclerosis, Diffuse Systemic; Sclerosis, Progressive
Interventions Ixazomib
Updated 8 times since 2021 Last updated: Mar 19, 2025 Started: Apr 28, 2021 Primary completion: Feb 23, 2024 Completion: Feb 23, 2024
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Low enrollment

This PHASE2 trial investigates Diffuse Cutaneous Scleroderma and Diffuse Cutaneous Systemic Sclerosis and is currently terminated or withdrawn. Michael M. Pham leads this study, which shows 8 recorded versions since 2021 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~May 2021 – ~Jun 2021 · 31 days · monthly snapshotRecruiting~Jun 2021 – ~Jun 2022 · 12 months · monthly snapshotRecruiting~Jun 2022 – ~May 2023 · 11 months · monthly snapshotRecruiting~May 2023 – ~May 2024 · 12 months · monthly snapshotRecruiting~May 2024 – ~Jul 2024 · 2 months · monthly snapshotTerminated~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotTerminated~Sep 2024 – ~May 2025 · 8 months · monthly snapshotTerminated~May 2025 – present · 14 months · monthly snapshotTerminated

Change History

8 versions recorded

  1. May 2025 — Present [monthly]

    Terminated PHASE2

  2. Sep 2024 — May 2025 [monthly]

    Terminated PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE2

  4. May 2024 — Jul 2024 [monthly]

    Terminated PHASE2

    Status: Recruiting → Terminated

  5. May 2023 — May 2024 [monthly]

    Recruiting PHASE2

▶ Show 3 earlier versions

  1. Jun 2022 — May 2023 [monthly]

    Recruiting PHASE2

  2. Jun 2021 — Jun 2022 [monthly]

    Recruiting PHASE2

  3. May 2021 — Jun 2021 [monthly]

    Recruiting PHASE2

    First recorded

Apr 2021

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Michael M. Pham
Data source: Mayo Clinic

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations